Stealth surgical reconstruction startup Tela-Bio raises $45.4M

Tela Bio, a Pennsylvania-based surgical reconstruction startup in stealth mode, raised $45.4 million from 29 investors, according to an SEC filing. According to earlier filings, Tela Bio previously raised $6 million in 2013 and $16.1 million in 2012. The company is reportedly led by Antony Koblish, who previously headed orthobiologics company OrthoVita that was sold to Stryker ($SYK) for $316 million in 2011. Koblish may have turned down a $400,000 annual salary offer to remain with Stryker to found the startup instead. More

Suggested Articles

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.

The dream of a comfortable, tabletop blood testing device, needing only a few drops taken from a finger and a handful of minutes, has now arrived.

Novartis is now teaming up with Amazon’s mammoth cloud computing division to overhaul its manufacturing, supply and business operations.